These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 14107743)

  • 1. INTERNATIONAL STANDARDS FOR ANTI-POLIOVIRUS SERA TYPES 1, 2 AND 3.
    LYNG J; BENTZON MW
    Bull World Health Organ; 1963; 29(6):711-20. PubMed ID: 14107743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ANTIGENIC DIFFERENTIATION OF POLIOVIRUSES BY ABSORBED HYPERIMMUNE SERA. I. ANTIGENIC DIFFERENTIATION OF TYPE I STRAINS OF DIVERSE ORIGIN.
    EYLAN E; FOGEL A; DUKLER R; RANNON L
    J Immunol; 1965 Jul; 95():171-80. PubMed ID: 14328695
    [No Abstract]   [Full Text] [Related]  

  • 3. [ON THE VIABILITY AND RESISTANCE OF VACCINAL STRAINS OF POLIOVIRUSES IN THE EXTERNAL ENVIRONMENT].
    BYCHKOVSKAIA OV; BABINA NS; IVANOVA OD; KISELEVA LF
    Gig Sanit; 1964 Aug; 29():45-9. PubMed ID: 14249261
    [No Abstract]   [Full Text] [Related]  

  • 4. ANTIGENIC VARIATIONS AMONG TYPE III POLIOMYELITIS VIRUSES.
    DEIBEL R; MACDONALD D
    N Y State J Med; 1964 Aug; 64():2058-65. PubMed ID: 14180893
    [No Abstract]   [Full Text] [Related]  

  • 5. An international collaborative study of the assay of the potency of poliomyelitis sera.
    BENTZON MW; EVANS DG; MAALOE O; PERKINS FT; SPAUN J
    Bull World Health Organ; 1962; 26(3):341-55. PubMed ID: 13867397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Second International Standard for anti-poliovirus sera types 1, 2 and 3.
    Wood DJ; Heath AB
    Biologicals; 1992 Sep; 20(3):203-11. PubMed ID: 1333776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PREPARATION AND ASSAY OF THE INTERNATIONAL STANDARDS FOR CLOSTRIDIUM BOTULINUM TYPES A, B, C, D AND E ANTITOXINS.
    BOWMER EJ
    Bull World Health Organ; 1963; 29(6):701-9. PubMed ID: 14107742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Some aspects of the monkey neurovirulence test used for the assessment of oral poliovirus vaccines.
    Furesz J; Contreras G
    Dev Biol Stand; 1993; 78():61-70. PubMed ID: 8388832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PEDIATRIC IMMUNIZATIONS.
    MCALLISTER RM
    World Wide Abstr Gen Med; 1964 Sep; 7():8-17. PubMed ID: 14200187
    [No Abstract]   [Full Text] [Related]  

  • 10. STRAIN SPECIFICITY OF TYPE 1 NEUTRALIZING ANTIBODIES DEVELOPING IN CHILDREN FED WITH TYPE 1 SABIN'S ATTENUATED VIRUS (LSC 2AB).
    VONKA V; TARABCAK M; JANDA Z
    Arch Gesamte Virusforsch; 1964; 14():169-76. PubMed ID: 14141577
    [No Abstract]   [Full Text] [Related]  

  • 11. [EVALUATION OF NEURAL LESIONS IN MONKEYS INOCULATED WITH SABIN POLIOVIRUS VACCINE].
    LUSSIER G; PAVILANIS V; DIFRANCO E
    Rev Can Biol; 1964 Sep; 23():323-32. PubMed ID: 14237165
    [No Abstract]   [Full Text] [Related]  

  • 12. Preparation and standardization of antiserums prepared with the three known types to poliomyelitis viruses.
    WENNER HA; MILLER CA; KAMITSUKA P; WILSON JC
    Am J Hyg; 1954 Mar; 59(2):221-35. PubMed ID: 13138587
    [No Abstract]   [Full Text] [Related]  

  • 13. A new WHO International Reference Reagent for use in potency assays of inactivated poliomyelitis vaccine.
    Wood DJ; Heath AB; Kersten GF; Hazendonk T; Lantinga M; Beuvery EC
    Biologicals; 1997 Mar; 25(1):59-64. PubMed ID: 9167009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A COMPARISON OF THE REACTIVITY OF POLIOVIRUS COMPLEMENT-FIXING ANTIGENS (NATIVE, HEATED AND SUCROSE DENSITY GRADIENT C AND D) WITH HUMAN SERA.
    LENNETTE EH; SCHMIDT NJ; MAGOFFIN RL; HAGENS SJ; DUKELLIS EJ
    J Immunol; 1964 Feb; 92():261-74. PubMed ID: 14160447
    [No Abstract]   [Full Text] [Related]  

  • 15. Collaborative study for the establishment of the Ph. Eur. BRP for oral poliomyelitis vaccine (OPV) Batch 3 for use in the potency assay.
    Buchheit KH; Daas A; Stalder J
    Pharmeuropa Spec Issue Biol; 2002 Jun; 2002(1):67-91. PubMed ID: 12448032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TRIVALENT ORAL POLIO VACCINE: CLINICAL TRIAL OF A NEW FORMULATION.
    BURKE DM; GOW RC
    Clin Pediatr (Phila); 1963 Sep; 2():517-20. PubMed ID: 14047178
    [No Abstract]   [Full Text] [Related]  

  • 17. European Pharmacopoeia biological reference preparation for poliomyelitis vaccine (inactivated): collaborative study for the establishment of batch No. 3.
    Martin J; Daas A; Milne C
    Pharmeur Bio Sci Notes; 2016; 2016():135-150. PubMed ID: 28279255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Calibration of Ph. Eur. BRP batch 4 for oral poliomyelitis vaccine (OPV).
    Fiore L; De Dominicis A; Daas A; Costanzo A
    Pharmeur Bio Sci Notes; 2014; 2014():18-38. PubMed ID: 25655241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Repertoire of antibodies against type 1 poliovirus in human sera.
    Rezapkin G; Neverov A; Cherkasova E; Vidor E; Sarafanov A; Kouiavskaia D; Dragunsky E; Chumakov K
    J Virol Methods; 2010 Nov; 169(2):322-31. PubMed ID: 20691212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serodifferentiation of poliovirus strains for studies of oral vaccine.
    GELFAND HM; NAKANO JH; COLE JT
    Public Health Rep (1896); 1962 Nov; 77(11):941-6. PubMed ID: 13947055
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.